Both Parkinson's disease, and the drugs used in its treatment appear to affect respiration and sleep. Upper airway obstruction as a result of antiparkinsonian medication withdrawal or manipulation is an uncommon phenomenon 2 , there being only one previous report in the anaesthetic literature of upper airway obstruction occurring in a patient with this disease. 3 A case of preoperative upper airway obstruction occurring in a patient with Parkinson's disease who was fasting for surgery is presented.
CASE REPORT
A 64-year-old non-English-speaking man presented to hospital with a history of a fractured left neck of femur sustained three weeks previously while overseas. He had refused surgery and had been treated with NSAIDs. Past medical history included a 24-year history of idiopathic Parkinson's disease for which he was being treated with levodopa (L-dopa) 250 mg/carbidopa 25 mg with doses at 0500, 1200, 1730 (double dose) and 2200 hours, benzhexol 5 mg mane; amantadine 100 mg mane; and amitriptyline 25 mg mane. He had no previous history of cardiorespiratory disease or previous hospitalizations.
Following admission, consent for surgical repair of his fracture was obtained and he was fasted for surgery. Later that day surgery was postponed due to lack of available operating theatre time. The following day he was again fasted from 0800 hours. At 1800 hours the cardiac arrest team was called. On arrival the patient was rigid, diaphoretic, and had an obviously obstructed upper airway. Arterial blood gases (ABGs) taken at this time showed pH 7.09, PC0 2 97 mmHg, P0 2 37 mmHg and Sp02 53%. He was afebrile and tachycardic. Jaw thrust re-established his airway and Sa02 rapidly increased to 100% on oxygen 10 litres per minute via a Hudson mask. A 12-lead electrocardiograph showed sinus tachycardia but was otherwise normal. A mobile supine AP chest X-ray showed poor inspiratory effort but lungfields were clear. The patient was awake but unable to communicate and able to maintain his own airway without assistance. A nasopharyngeal airway gave only partial relief. Benztropine 4 mg in divided doses was given intravenously with some slight relief of rigidity. He was transferred to the Intensive Care Unit (ICU) for further management.
In ICU, the patient's airway was maintained with jaw thrust while a nasogastric tube was inserted and medications recommenced. A fibreoptic bronchoscope introduced nasally revealed a narrow hypopharynx but otherwise normal supraglottic structures and abducted vocal cords. A nasotracheal tube was introduced to secure the airway and good gas exchange was achieved with spontaneous respiration, Fi0 2 of 30% and 10 cm of CPAP.
History from the patient's relatives and examination of his medical records revealed that five doses of levodopa/carbidopa had been omitted since his admission and that he had not received any dopamine antagonists.
The following day the trachea was extubated and the patient transferred to the ward with a nasopharyngeal airway in situ. Over the ensuing 48 hours a further three episodes of respiratory arrest occurred requiring arrest team intervention. Management continued in the ward with continuous pulse oximetry monitoring, fourhourly changes of nasopharyngeal airways, posturing of the patient and restriction of opioid analgesia. Antiparkinsonian medications were continued. Further investigations included a lateral airways X-ray which was normal. A provisional diagnosis of obstructive sleep apnoea was made and nasal CPAP was commenced. Nasal CPAP was poorly tolerated but no further significant episodes of upper airway obstruction occurred. One week after admission the patient underwent surgical repair of the fractured neck of femur under lumbar epidural block. Recovery was slow, requiring protracted rehabilitation and readjustment of antiparkinsonian medications for persistent immobility.
A subsequent sleep study showed poor sleep efficiency, no REM sleep, a decrease in Sa02 of less than 3070 and normal ABGs on room air. Analysis showed that the patient had mild obstructive sleep apnoea. A recommendation to cease nasal CPAP was made.
DISCUSSION
Respiratory abnormalities have been noted in patients with Parkinson's disease since its initial description in 1817 and these problems commonly contribute to morbidity and mortality'. In the 1960s, several studies identified an obstructive respiratory defect in parkinsonian patients. These were postulated to be due to either parasympathetic hyperactivity5 or to coexisting chronic obstructive lung disease 6 .
Vincken and colleagues (1984)' were the first to describe involvement of upper airway muscles in extrapyramidal disorders. They tested pulmonary function in 27 patients with extrapyramidal disorders with flow volume loops and direct fibreoptic visualization of the upper airway. The configuration of the flow-volume loop was frequently abnormal. Using fibreoptic endoscopy, diaphragm cinefluroscopy, and oesophageal pressure monitoring, flow alterations were shown to be due to involvement of the striated musculature surrounding the upper airway rather than the involvement of the chest wall muscles. Subclinical upper airway obstruction has been detected using pulmonary function testing in Parkinsonian patients asymptomatic for pulmonary disease', and electromyographic studies have confirmed phasic activity of muscles involved in maintenance of the upper airways. These studies suggest that Parkinson's disease and other extrapyramidal disorders can cause a dysfunctional upper airway obstruction of varying degree that can be severe enough to limit airflow.
Respiratory dysfunction has also been described as a result of manipulation of anti parkinsonian medications. Excessive L-dopa may result in respiratory dyskinesia characterized by dyspnoea and rapid, shallow irregular respiration 9 . Conversely, L-dopa withdrawal has been associated with respiratory dysfunction, particularly upper airway obstructionlO,ll. More recently, reversibility of abnormal flow-volume loops and airflow limitation with L-dopa treatment has been demonstrated' 2. Similarly anecdotal reports of upper airway obstruction occurring from dopamine agonist withdrawal or manipulation have appeared in the literature'J. Upper airway obstruction due to dopamine antagonist therapy (haloperidol) has also been reported 14. Levodopa has significantly improved the functional status of patients with Parkinson's disease. Neither L-dopa nor L-dopa/carbidopa are available in parenteral formulation because of their poor water solubility and susceptibility to oxidation. This presents a potential difficulty for patients who are unable to continue their oral medications such as in the perioperative period due to fasting or gut failure. Although there is no parenteral L-dopa formulation available, extemporaneous solutions have been used for both intravenous and enteral routes of administration and have been shown to be stable for at least 24 hours'6. Continuous intravenous infusion of L-dopa has been used in the perioperative management of parkinsonian patients but this is disadvantaged by the lack of an intravenous formulation of a decarboxylase inhibitor, the potential for a significant fluid load if high L-dopa requirements occur 17 and sclerosis of peripheral veins.
Continous enteric infusion of a L-dopa/carbidopa dispersion has been used in the management of the "on-off" phenomenon in severe Parkinson's disease's. However, enteric infusions require instrumentation of the gut and are obviously of little use in those patients who have impaired gastrointestinal absorption.
Apomorphine, a D 1 , D2 agonist, has recently been reintroduced as a treatment in advanced Parkinson's disease for the reduction of "off" period asociated rigidity'9. It has proved efficacious as a continuous subcutaneous infusion in the perioperative period in patients with severe forms of the disease 2o • It has been available without restriction in Australia in a parenteral formulation since November 1993.
Our patient, with a long history of idiopathic Parkinson's disease, had several episodes of severe potentially life-threatening upper airway obstruction relieved initially with tracheal intubation. This would appear to have been precipitated by withdrawal of L-dopa medication due to prolonged preoperative fasting. Although obstructive sleep apnoea was diagnosed in our patient, this was not supported by a formal sleep study.
There is a wide variey of respiratory abnormalities in parkinsonian patients. Drug manipulation may exacerbate these abnormalities, and anaesthetists should be aware of these potentially adverse effects in patients presenting for surgery. Antiparkinsonian medications should be continued throughout the perioperative period if possible. For those patients unable to take their usual oral medications, parenteral apomorphine would seem to be the agent of choice because of its availability, efficacy and ease of administration.
